

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* DOBMEIER ERIC (Last) (First) (Middle) C/O CHINOOK THERAPEUTICS, INC. 400 FAIRVIEW AVE. NO., 9TH FLOOR (Street) SEATTLE WA 98109 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol CHINOOK THERAPEUTICS, INC. [KDNV]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) President, CEO
	3. Date of Earliest Transaction (Month/Day/Year) 08/11/2023	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	
	Rule 10b5-1(c) Transaction Indication <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/11/2023		D		301,138	D	(1)	0	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)	Date Exercisable	Expiration Date				
Stock Option (Right to Buy)	\$0.35	08/11/2023		D		353,358	(2)	06/05/2029	Common Stock	353,358	\$39.65	0	D	
Stock Option (Right to Buy)	\$0.42	08/11/2023		D		313,555	(3)	03/17/2030	Common Stock	313,555	\$39.58	0	D	
Stock Option (Right to Buy)	\$14.77	08/11/2023		D		271,647	(4)	10/05/2030	Common Stock	271,647	\$25.23	0	D	
Stock Option (Right to Buy)	\$15.14	08/11/2023		D		178,600	(5)	02/09/2031	Common Stock	178,600	\$24.86	0	D	
Stock Option (Right to Buy)	\$12.9	08/11/2023		D		300,000	(6)	01/30/2032	Common Stock	300,000	\$27.1	0	D	
Stock Option (Right to Buy)	\$25.27	08/11/2023		D		255,150	(7)	01/30/2033	Common Stock	255,150	\$14.73	0	D	
Restricted Stock Units	(8)	08/11/2023		D		30,797	(9)	(9)	Common Stock	30,797	(9)	0	D	
Restricted Stock Units	(8)	08/11/2023		D		20,248	(10)	(10)	Common Stock	20,248	(10)	0	D	
Restricted Stock Units	(8)	08/11/2023		D		50,001	(11)	(11)	Common Stock	50,001	(11)	0	D	
Restricted Stock Units	(8)	08/11/2023		D		64,050 ⁽¹²⁾	(12)	(12)	Common Stock	64,050	(12)	0	D	
Restricted Stock Units	(8)	08/11/2023		D		11,300	(13)	(13)	Common Stock	11,300	(13)	0	D	

Explanation of Responses:

1. The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) \$40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.

